Developer docs
API playgroundTry for free, no card

Search company profiles

Sparrow Pharmaceuticals

Full company profile

uuid00002cm

Namestring
Sparrow Pharmaceuticals
Legal namestring
Sparrow Pharmaceuticals
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cardiometabolic therapeutics based on the inhibition of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) to reduce intracellular cortisol in metabolically active tissues. The company's lead candidate, clofutriben (formerly SPI-62), is a once-daily, oral, highly potent and selective HSD-1 inhibitor designed to lower intracellular cortisol levels in liver, fat, pancreas, muscle, bone, and brain without suppressing systemic cortisol sufficiently to cause adrenal insufficiency. Clofutriben is in development across four indications: type 2 diabetes with elevated cortisol (Phase 2b CAPTAIN-T2D), endogenous Cushing's syndrome (Phase 2 RESCUE), autonomous cortisol secretion (Phase 2 ACSpire and investigator-led DC-MACS in the UK), and polymyalgia rheumatica as a fixed-dose combination with prednisolone (SPI-47 / Phase 2 PROST!).

The company is pre-revenue and operates with a 1-10 employee team, conducting clinical trials in partnership with academic medical centers (including the Universities of Oxford and Sheffield), contract research organizations, and investigator sites. Commercial go-to-market upon regulatory approval is planned through traditional pharmaceutical sales channels targeting endocrinologists and diabetologists. Sparrow has raised approximately $145.3 million across four funding rounds from institutional life-sciences investors (OrbiMed, RA Capital Management, Forbion, RiverVest Venture Partners, and U.S. Venture Partners), with the most recent $95 million Series B closed in September 2025 to fund the Phase 2b CAPTAIN-T2D program through expected 2027 data. The company holds FDA Orphan Drug Designation for clofutriben in endogenous Cushing's syndrome and EMA Small and Medium-sized Enterprise (SME) status.

Short descriptiontext

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing clofutriben, a once-daily oral HSD-1 inhibitor, for type 2 diabetes with elevated cortisol, Cushing's syndrome, autonomous cortisol secretion, and polymyalgia rheumatica.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
HSD-1 inhibitors, cardiometabolic therapeutics, type 2 diabetes drugs, Cushing syndrome treatment, polymyalgia rheumatica therapy
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Scientific Research and Development Services5417
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Cardiometabolic Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company planning to commercialize drug candidates upon regulatory approval. Lead candidate clofutriben is in Phase 2b development for type 2 diabetes with elevated cortisol, with additional indications in endogenous Cushing's syndrome, autonomous cortisol secretion, and polymyalgia rheumatica.

sparrowpharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1SPI-62
Description

Original development code name for clofutriben, a potent and selective HSD-1 inhibitor

sparrowpharma.com
+2 more records
Core offering1 text field

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cardiometabolic therapeutics centered on its lead candidate clofutriben, an oral once-daily selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) that reduces intracellular cortisol in metabolically active tissues. The compound is being developed for type 2 diabetes with elevated cortisol, endogenous Cushing's syndrome, autonomous cortisol secretion, and as part of a fixed-dose combination (SPI-47) with prednisolone for polymyalgia rheumatica.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 77.1% of 397 screened patients with difficult-to-control Type 2 diabetes had elevated cortisol levels associated with increased cardiovascular disease prevalence
+4 more records
Product overview1 text field

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cardiometabolic therapeutics. The company's core product portfolio centers on clofutriben (SPI-62), a novel HSD-1 inhibitor that reduces intracellular cortisol levels. Clofutriben is being developed both as a standalone therapy for type 2 diabetes with elevated cortisol, endogenous Cushing's syndrome, and autonomous cortisol secretion, and as a fixed-dose combination (SPI-47) with prednisolone for polymyalgia rheumatica. The company is conducting multiple Phase 2 clinical trials including CAPTAIN-T2D, RESCUE, PROST!, ACSpire, and DC-MACS.

Product and service2 records
1Clofutriben (SPI-62)
CategorySmall-molecule cardiometabolic drug candidate
Description

Clofutriben is a once-daily, oral, highly potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) designed to reduce intracellular cortisol levels in liver, fat, pancreas, muscle, bone, and brain. It is being developed for patients with inadequately controlled type 2 diabetes with elevated cortisol, endogenous Cushing's syndrome, autonomous cortisol secretion, and (in combination) polymyalgia rheumatica.

2SPI-47
CategoryFixed-dose combination drug candidate
Description

SPI-47 is a fixed-dose combination of clofutriben (SPI-62) and prednisolone in development for polymyalgia rheumatica, designed to maintain the anti-inflammatory efficacy of prednisolone while reducing its metabolic side effects such as glucocorticoid-induced diabetes, hypertension, osteoporosis, and weight gain.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-11
Description

Sparrow is collaborating with University of Oxford on DC-MACS, an investigator-led Phase 2 clinical study of clofutriben for the treatment of autonomous cortisol secretion (ACS). The study is led by Prof. Jeremy Tomlinson, PhD, a pioneering HSD-1 researcher who first described a patient with a Cushing's tumor but no signs or symptoms of Cushing's syndrome because of HSD-1 deficiency. The study is supported by the UK Research and Innovation Medical Research Council and conducted in NIHR-supported clinical research facilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-11
Description

Sparrow is collaborating with University of Sheffield on DC-MACS, a Phase 2 clinical study of clofutriben for autonomous cortisol secretion. The study is led by Prof. John Newell-Price, PhD, the current President of the Endocrine Society. The study is conducted jointly in NIHR-supported clinical research facilities in both Oxford and Sheffield, with 40 patients across two sites (Sheffield Teaching Hospitals NHS Foundation Trust and Oxford University Hospitals NHS Foundation Trust).

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Corcept is the established leader in cortisol modulation, with Korlym (mifepristone) approved for Cushing's syndrome. Both companies target cortisol-driven disease, though Corcept uses glucocorticoid receptor antagonism while Sparrow targets intracellular cortisol generation via HSD-1 inhibition.

TypeDirect peer
Description

Xeris markets Recorlev (levoketoconazole) for endogenous Cushing's syndrome, directly overlapping Sparrow's lead orphan indication. Both are pursuing novel mechanisms for cortisol excess in a similar endocrinologist prescriber base.

TypeDirect peer
Description

Recordati markets Isturisa (osilodrostat) for Cushing's syndrome and has a broad endocrine rare disease portfolio. Directly comparable as a competitor in the same Cushing's syndrome indication, with established commercial infrastructure Sparrow lacks.

TypeEmerging player
Description

Mineralys is developing aldosterone synthase inhibitors (lorundrostat) for hypertension and cardiorenal conditions, sharing the hormonal-modulation therapeutic approach in cardiometabolic disease. Both are clinical-stage biotechs targeting underserved endocrine-driven patient populations.

TypeEmerging player
Description

Crinetics develops oral small molecule therapies for rare endocrine diseases, with paltusotine approved for acromegaly. Comparable as a clinical-stage specialist in endocrine disorders with a similar go-to-market focus on endocrinologists.

TypeBroad incumbent
Description

Madrigal commercializes Rezdiffra (resmetirom) for MASH, a cardiometabolic liver disease. Comparable as a recently-commercialized clinical-stage-to-commercial biotech in the cardiometabolic specialty space with novel mechanism credentials.

TypeBroad incumbent
Description

Lilly markets Mounjaro/Zepbound (tirzepatide), the dominant GLP-1 in T2D and obesity. Represents the primary competitive threat to clofutriben's eventual T2D commercial opportunity given Lilly's installed prescriber relationships and formulary position.

TypeBroad incumbent
Description

Novo Nordisk markets Ozempic/Wegovy (semaglutide) and the broader GLP-1 franchise that has redefined T2D treatment standards. Comparable as the incumbent whose therapeutic paradigm Sparrow must differentiate against.

TypeEmerging player
Description

Soleno is a small clinical-stage biopharma with DCCR (diazoxide choline) for Prader-Willi syndrome — a rare endocrine/metabolic disorder. Comparable as a focused, small-team biotech developing a single targeted molecule for an underserved endocrine patient population.

TypeOthers
Description

Pfizer previously developed HSD-1 inhibitors (e.g., PF-915275) for metabolic disease that did not advance commercially. Comparable as a historical investor in the HSD-1 mechanism and a major incumbent whose prior failures inform the regulatory and clinical landscape Sparrow is entering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sparrow Pharmaceuticals

Cardiometabolic Biopharmaceuticalssparrowpharma.com

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing clofutriben, a once-daily oral HSD-1 inhibitor, for type 2 diabetes with elevated cortisol, Cushing's syndrome, autonomous cortisol secretion, and polymyalgia rheumatica.

What Sparrow Pharmaceuticals does

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cardiometabolic therapeutics based on the inhibition of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) to reduce intracellular cortisol in metabolically active tissues. The company's lead candidate, clofutriben (formerly SPI-62), is a once-daily, oral, highly potent and selective HSD-1 inhibitor designed to lower intracellular cortisol levels in liver, fat, pancreas, muscle, bone, and brain without suppressing systemic cortisol sufficiently to cause adrenal insufficiency. Clofutriben is in development across four indications: type 2 diabetes with elevated cortisol (Phase 2b CAPTAIN-T2D), endogenous Cushing's syndrome (Phase 2 RESCUE), autonomous cortisol secretion (Phase 2 ACSpire and investigator-led DC-MACS in the UK), and polymyalgia rheumatica as a fixed-dose combination with prednisolone (SPI-47 / Phase 2 PROST!).

The company is pre-revenue and operates with a 1-10 employee team, conducting clinical trials in partnership with academic medical centers (including the Universities of Oxford and Sheffield), contract research organizations, and investigator sites. Commercial go-to-market upon regulatory approval is planned through traditional pharmaceutical sales channels targeting endocrinologists and diabetologists. Sparrow has raised approximately $145.3 million across four funding rounds from institutional life-sciences investors (OrbiMed, RA Capital Management, Forbion, RiverVest Venture Partners, and U.S. Venture Partners), with the most recent $95 million Series B closed in September 2025 to fund the Phase 2b CAPTAIN-T2D program through expected 2027 data. The company holds FDA Orphan Drug Designation for clofutriben in endogenous Cushing's syndrome and EMA Small and Medium-sized Enterprise (SME) status.

Sparrow Pharmaceuticals firmographics

Firmographics
Name
Sparrow Pharmaceuticals
Legal name
Sparrow Pharmaceuticals
Website
https://sparrowpharma.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing clofutriben, a once-daily oral HSD-1 inhibitor, for type 2 diabetes with elevated cortisol, Cushing's syndrome, autonomous cortisol secretion, and polymyalgia rheumatica.
Ownership category
akta.pro rank

Sparrow Pharmaceuticals industry classification

Industry
Product category
Cardiometabolic Biopharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Scientific Research and Development Services (5417)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • HSD-1 inhibitors
  • Cardiometabolic therapeutics
  • Type 2 diabetes drugs
  • Cushing syndrome treatment
  • Polymyalgia rheumatica therapy

Where Sparrow Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Sparrow Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company planning to commercialize drug candidates upon regulatory approval. Lead candidate clofutriben is in Phase 2b development for type 2 diabetes with elevated cortisol, with additional indications in endogenous Cushing's syndrome, autonomous cortisol secretion, and polymyalgia rheumatica.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Sparrow Pharmaceuticals product offering

Product offering

Core offering

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cardiometabolic therapeutics centered on its lead candidate clofutriben, an oral once-daily selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) that reduces intracellular cortisol in metabolically active tissues. The compound is being developed for type 2 diabetes with elevated cortisol, endogenous Cushing's syndrome, autonomous cortisol secretion, and as part of a fixed-dose combination (SPI-47) with prednisolone for polymyalgia rheumatica.

Product overview

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cardiometabolic therapeutics. The company's core product portfolio centers on clofutriben (SPI-62), a novel HSD-1 inhibitor that reduces intracellular cortisol levels. Clofutriben is being developed both as a standalone therapy for type 2 diabetes with elevated cortisol, endogenous Cushing's syndrome, and autonomous cortisol secretion, and as a fixed-dose combination (SPI-47) with prednisolone for polymyalgia rheumatica. The company is conducting multiple Phase 2 clinical trials including CAPTAIN-T2D, RESCUE, PROST!, ACSpire, and DC-MACS.

Differentiator

Problem solved

Functional benefit

Brands

  • SPI-62: Original development code name for clofutriben, a potent and selective HSD-1 inhibitor
  • SPI-47
  • clofutriben

Products and services

  • Clofutriben (SPI-62) Clofutriben is a once-daily, oral, highly potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) designed to reduce intracellular cortisol levels in liver, fat, pancreas, muscle, bone, and brain. It is being developed for patients with inadequately controlled type 2 diabetes with elevated cortisol, endogenous Cushing's syndrome, autonomous cortisol secretion, and (in combination) polymyalgia rheumatica.
  • SPI-47 SPI-47 is a fixed-dose combination of clofutriben (SPI-62) and prednisolone in development for polymyalgia rheumatica, designed to maintain the anti-inflammatory efficacy of prednisolone while reducing its metabolic side effects such as glucocorticoid-induced diabetes, hypertension, osteoporosis, and weight gain.

Quantifiable outcome

  • 77.1% of 397 screened patients with difficult-to-control Type 2 diabetes had elevated cortisol levels associated with increased cardiovascular disease prevalence
  • +4 more outcomes

Companies that use Sparrow Pharmaceuticals

Customer profile

Segments4 records

Ideal customer profiles2 records

Sparrow Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sparrow Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • University of OxfordcoreStrategic or Co-development Partner · 11 December 2024Sparrow is collaborating with University of Oxford on DC-MACS, an investigator-led Phase 2 clinical study of clofutriben for the treatment of autonomous cortisol secretion (ACS). The study is led by Prof. Jeremy Tomlinson, PhD, a pioneering HSD-1 researcher who first described a patient with a Cushing's tumor but no signs or symptoms of Cushing's syndrome because of HSD-1 deficiency. The study is supported by the UK Research and Innovation Medical Research Council and conducted in NIHR-supported clinical research facilities.
  • University of SheffieldcoreStrategic or Co-development Partner · 11 December 2024Sparrow is collaborating with University of Sheffield on DC-MACS, a Phase 2 clinical study of clofutriben for autonomous cortisol secretion. The study is led by Prof. John Newell-Price, PhD, the current President of the Endocrine Society. The study is conducted jointly in NIHR-supported clinical research facilities in both Oxford and Sheffield, with 40 patients across two sites (Sheffield Teaching Hospitals NHS Foundation Trust and Oxford University Hospitals NHS Foundation Trust).

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Sparrow Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Corcept Therapeutics: Corcept is the established leader in cortisol modulation, with Korlym (mifepristone) approved for Cushing's syndrome. Both companies target cortisol-driven disease, though Corcept uses glucocorticoid receptor antagonism while Sparrow targets intracellular cortisol generation via HSD-1 inhibition.
  • Xeris Biopharma: Xeris markets Recorlev (levoketoconazole) for endogenous Cushing's syndrome, directly overlapping Sparrow's lead orphan indication. Both are pursuing novel mechanisms for cortisol excess in a similar endocrinologist prescriber base.
  • Recordati: Recordati markets Isturisa (osilodrostat) for Cushing's syndrome and has a broad endocrine rare disease portfolio. Directly comparable as a competitor in the same Cushing's syndrome indication, with established commercial infrastructure Sparrow lacks.

Emerging players

  • Mineralys Therapeutics: Mineralys is developing aldosterone synthase inhibitors (lorundrostat) for hypertension and cardiorenal conditions, sharing the hormonal-modulation therapeutic approach in cardiometabolic disease. Both are clinical-stage biotechs targeting underserved endocrine-driven patient populations.
  • Crinetics Pharmaceuticals: Crinetics develops oral small molecule therapies for rare endocrine diseases, with paltusotine approved for acromegaly. Comparable as a clinical-stage specialist in endocrine disorders with a similar go-to-market focus on endocrinologists.
  • Soleno Therapeutics: Soleno is a small clinical-stage biopharma with DCCR (diazoxide choline) for Prader-Willi syndrome — a rare endocrine/metabolic disorder. Comparable as a focused, small-team biotech developing a single targeted molecule for an underserved endocrine patient population.

Broad incumbents

  • Madrigal Pharmaceuticals: Madrigal commercializes Rezdiffra (resmetirom) for MASH, a cardiometabolic liver disease. Comparable as a recently-commercialized clinical-stage-to-commercial biotech in the cardiometabolic specialty space with novel mechanism credentials.
  • Eli Lilly: Lilly markets Mounjaro/Zepbound (tirzepatide), the dominant GLP-1 in T2D and obesity. Represents the primary competitive threat to clofutriben's eventual T2D commercial opportunity given Lilly's installed prescriber relationships and formulary position.
  • Novo Nordisk: Novo Nordisk markets Ozempic/Wegovy (semaglutide) and the broader GLP-1 franchise that has redefined T2D treatment standards. Comparable as the incumbent whose therapeutic paradigm Sparrow must differentiate against.

Others

  • Pfizer: Pfizer previously developed HSD-1 inhibitors (e.g., PF-915275) for metabolic disease that did not advance commercially. Comparable as a historical investor in the HSD-1 mechanism and a major incumbent whose prior failures inform the regulatory and clinical landscape Sparrow is entering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Sparrow Pharmaceuticals social profiles

Digital presence

Sparrow Pharmaceuticals compliance and trust

Trust signal

Compliance2 records

Sparrow Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sparrow Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles12 records

Sparrow Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sparrow Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sparrow Pharmaceuticals

What does Sparrow Pharmaceuticals do?

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cardiometabolic therapeutics centered on its lead candidate clofutriben, an oral once-daily selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) that reduces intracellular cortisol in metabolically active tissues. The compound is being developed for type 2 diabetes with elevated cortisol, endogenous Cushing's syndrome, autonomous cortisol secretion, and as part of a fixed-dose combination (SPI-47) with prednisolone for polymyalgia rheumatica.

Is Sparrow Pharmaceuticals a public or private company?

Sparrow Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sparrow Pharmaceuticals founded?

Sparrow Pharmaceuticals was founded in 2021. It employs 11 to 50 people.

Where is Sparrow Pharmaceuticals based?

Sparrow Pharmaceuticals is headquartered in Boston, United States, in the North America region.

How does Sparrow Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Sparrow Pharmaceuticals's main competitors?

Direct peers on record are Corcept Therapeutics, Xeris Biopharma and Recordati. Emerging players are Mineralys Therapeutics, Crinetics Pharmaceuticals and Soleno Therapeutics. Broad incumbents are Madrigal Pharmaceuticals, Eli Lilly and Novo Nordisk. Pfizer is listed as an others.

Does Sparrow Pharmaceuticals have an API?

No public API is recorded for Sparrow Pharmaceuticals.

What industry is Sparrow Pharmaceuticals in?

Sparrow Pharmaceuticals's product category is Cardiometabolic Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialSparrow Pharmaceuticals Announces Expansion Cohorts In Phase 2B CAPTAIN-T2D Trial To Evaluate Clofutriben Across The Full Range Of Cortisol Levels In Difficult-To-Control Type 2 DiabetesSparrow Pharmaceuticals added expansion cohorts to its Phase 2b CAPTAIN-T2D trial of clofutriben, enrolling about 80 patients with post-DST cortisol at or below 1.8 μg/dL. The trial will evaluate whether the HSD-1 inhibitor's efficacy extends across the full range of cortisol levels in difficult-to-control type 2 diabetes.The Pharma LetterSparrow Pharma appoints George Eldridge as CFOSparrow Pharmaceuticals appointed George Eldridge as chief financial officer. Eldridge brings over two decades of biotechnology financial leadership, including experience guiding companies through successful initial public offerings.BioSpaceSparrow Pharmaceuticals Appoints George Eldridge as Chief Financial OfficerSparrow Pharmaceuticals appointed George Eldridge as Chief Financial Officer, bringing over two decades of biotech financial leadership. He previously guided Abcuro and Aerovate through IPOs. The company is advancing clofutriben for cardiometabolic disease.HCP LiveClofutriben Phase 2a Data Show Cardiometabolic Benefits in Type 2 DiabetesSparrow Pharmaceuticals announced positive phase 2a data for clofutriben, showing significant improvements in HbA1c, glucose, and total cholesterol in adults with type 2 diabetes during a trial. The data suggests that clofutriben could address treatment resistance and cardiometabolic dysfunction in patients, particularly those with elevated cortisol. This reinforces the potential of clofutriben as a therapeutic option for patients inadequately managed by current therapies.The Pharma LetterPositive Phase II data on Sparrow Pharma’s clofutriben in diabetesSparrow Pharmaceuticals announced positive Phase II clinical data for its investigational drug clofutriben in adults with type 2 diabetes at the 2026 American Diabetes Association Scientific Session. The treatment demonstrated statistically significant improvements in HbA1c and total cholesterol, with enhanced benefits observed in patients with elevated cortisol risk factors.BiggoRobert Jacks: The Biotech CEO Betting Cortisol, Not GLP-1, Is the Next Frontier in Diabetes — BigGo FinanceSparrow Pharmaceuticals CEO Robert Jacks has announced a strategic pivot towards targeting cortisol in type 2 diabetes patients, revealing data that over 50% of such patients exhibit unhealthy cortisol levels. The company's current drug, an HSD1 inhibitor, is in phase 2b trials and aims to complement GLP-1 drugs, addressing the treatment resistance seen in many diabetes patients. This move aligns with shifting investor interests from rare diseases to larger cardiometabolic indications.GlobeNewswireSparrow Pharmaceuticals Announces Interim CAPTAIN-T2D Data Validating High Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 DiabetesSparrow Pharmaceuticals announced interim data from Part 1 of the Phase 2b CAPTAIN-T2D trial, revealing that 77.1% of 397 screened patients with difficult-to-control Type 2 diabetes had elevated cortisol levels associated with increased cardiovascular disease prevalence. Patients with inadequately controlled T2D who also had hypertension or were using incretin agonists showed higher cortisol levels. The company stated these findings, along with Phase 2a data on their drug candidate clofutriben, strengthen the potential for targeting cortisol to address unmet medical needs in cardiometabolic disease.BioSpaceSparrow Pharmaceuticals Announces Interim CAPTAIN-T2D Data Validating High Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 DiabetesSparrow Pharmaceuticals presented interim data from CAPTAIN-T2D at ENDO 2026, showing 77.1% of 397 screened patients had elevated cortisol. The data also found higher cortisol in patients with hypertension or incretin agonist use. The company plans to evaluate clofutriben's impact on glycemic control in the trial's treatment phase.BioSpaceSparrow Pharmaceuticals Announces Phase 2a Data Showing Cardiometabolic Benefits of Clofutriben in Adults with Type 2 DiabetesSparrow Pharmaceuticals announced positive Phase 2a data for clofutriben, an HSD-1 inhibitor, in adults with type 2 diabetes at the 2026 ADA meeting. The 6-week trial showed statistically significant HbA1c and total cholesterol reductions, with numerically larger benefits in a subset with elevated cortisol risk factors. The company plans to expand into other cardiometabolic indications.BioSpaceSparrow Pharmaceuticals Announces Acceptance of Late-Breaking Presentation of Interim Part 1 Results from CAPTAIN-T2D at the Endocrine Society (ENDO) 2026 Annual MeetingSparrow Pharmaceuticals announced interim Part 1 results from the CAPTAIN-T2D trial at the Endocrine Society 2026 Annual Meeting in Chicago. The Phase 2b study evaluates clofutriben for glycemic control in type 2 diabetes with elevated cortisol. Part 1 screens for eligibility, with Part 2 randomized to clofutriben or placebo.